Monoclonal antibody to HER-2/neu receptor modulates repair of radiation- induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1347-1355

  Pietras, Richard J ^a   Poen, Joseph C ^b   Gallardo, David ^a   Wongvipat, P Nancy ^a   Lee, H Julie ^a   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPITOPE; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; RADIATION INJURY; RADIOSENSITIVITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL CYCLE; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RADIATION TOLERANCE; RADIATION, IONIZING; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033559619     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. N. Engl. J. Med., 333: 1444-1455, 1195.
2. Lichter, A. S., and Lawrence, T. S. Recent advances in radiation oncology. N. Engl. J. Med., 332: 371-379, 1995.
3. Canman, C. E., Gilmer, T. M., Coutts, S., and Kastan, M. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev., 9: 600-611, 1995.
4. Coussens, L., Yang-Feng, T. C., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Lieberman, T. A., Schlessinger, J., Francke, U., Leninson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
5. Slamon D. J., Clark, G. M., Wong, S. G., Levin, W., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
6. Slamon D. J., Godolphin, W., Jones, L., Holt, J., Wong, S., Keith, D., Levin, W., Stuart, S., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
7. Slamon, D., Press, M., Godolphin, W., Ramos, L., Haran, P., Shek, L., Stuart, S., and Ullrich, A. Studies of the HER-2/neu oncogene in human breast cancer. Cancer Cells. 7: 371-379, 1989.
8. Reese, D., and Slamon, D. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells, 15: 1-8, 1997.
9. DiFiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science (Washington DC), 237: 178-181, 1987.
10. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor receptor p185HER-2 causes transformation and tumorigenesis of NIH-3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
11. Chazin, V., Kaleko, M. Miller, A., and Slamon, D. J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene, 7: 1859-1865, 1992.
12. Pierce, J., Arnstein, P., DiMarco, E., Artrip, J., Kraus, M., Lonardo, K., DiFiore, P., and Aaronson, S. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene, 6, 1189-1194, 1991.
13. Ro, J., El-Naggar, A., Ro, J. Y., Blick, M., Frye, D., Fraschini, G., Fritsche, H., and Hortobagyi, G. c-erbB-2 Amplification in node-negative human breast cancer. Cancer Res., 49: 6941-6950, 1989.
14. Alfred, D. C. Clark, G. M., Tandon, A., Molina, R., Tormey, D., Osborne, C., Gilchrist, K., Mansour, E. G., Abeloff, M., Eudey, L., and McGuire, W. L. HER-2/ neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 599-608, 1992.
15. Gusterson, B., Gelber, R., Goldhirsch, A., Price, K., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M. Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst., J., Grigolato, P., Bettelheim, R., Neville, A., Burki, K., Castiglione, M., Collins, J., Lindtner, J., and Senn, H-J. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1059, 1992.
16. Haffty, B. G., Brown, F., Carter, D., and Flynn, S. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int. J. Radiat. Oncol. Biol. Phys., 35: 751-757, 1996.
17. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in nude mice. J. Natl. Cancer Inst. (Bethesda). 80: 1605-1611, 1988.
18. Christen, R. D., Hom, D. K., Porter, D. C., Andrews, P. A., MacLeod, C. L., Hafstrom, L., and Howell, S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 86: 1632-1640, 1991.
19. Kwock, T. T., and Sutherland, R. M. Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. J. Natl. Cancer Inst. (Bethesda), 81: 1020-1024, 1989.
20. Pirollo, K., Tong, Y., Villegas, Z., Chen, Y., and Chang, E. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat. Res., 135: 234-243, 1993.
21. Wollman, R., Yahalom, J., Maxy, R., Pinto, J., and Fuks, Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int. J. Radiat. Oncol. Biol. Phys., 30: 91-98, 1994.
22. Pietras, R. J., Fendly, B. M., Chazin, V., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
23. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J., Mischak, R., and Shawver, L. K. A monoclonal antibody against the c-crbB-2 protein enhances the cytotoxicity of cisdiamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
24. Jensen, L., and Linn, S. A Reduced rate of bulky DNA adduct removal is coincident with differentiation of human neuroblastoma cells induced by NGF. Mol. Cell. Biol., 8: 3964-3969, 1988.
25. Kastan, M., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. Participation of p53 protein in the cellular response to DNA damage Cancer Res., 51: 6304-6311, 1991.
26. Clarke, A., Purdie, C., Harrison, D., Morris, R., Bird, C., Hooper, M., and Wylie, A. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
27. Smith, M., Chen, I-T., Zhan, Q., O'Connor, P., and Fornace, A., Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene, 10: 1053-1059, 1995.
28. El-Diery, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J., Lin, D., Mercer, W., Kinzler, K., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
29. Chen, C., Oliner, J., Zhan, Q., Fornace, A., Vogelstein, B., and Kastan, M. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA, 91: 2684-2688, 1994.
30. Sachsenmaier, C., Radler-Pohl, A., Zinck, R., Nordheim, A., Herrlich, P., and Rahmsdorf, H. Involvement of growth factor receptors in the mammalian UVC response. Cell. 78: 963-972, 1994.
31. Liu, Y., Martindale, J., Gorospe, M., and Holbrook, N. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res., 56: 31-35, 1996.
32. Fendly, B. M., Winget, M., Hudziak, R., Lipari, M., Napier, M., and Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50: 1550-1558, 1990.
33. Carter, P., Presta, L., Gorman, C. M., Ridgway, J., Henner, D., Wong, W., Rowland, A. W., Knotts, C., Carver, M. E., and Shepard, H. M. Humanization of an anti-p185HER 2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4291, 1992.
34. Lewis, G., Lofgren, J., McMurtrey, A., Nuijens, A., Fendly, B., Bauer, K., and Sliwkowski, M. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of erbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56: 1457-1465, 1996.
35. Stammberger, I., Schmahl, W., and Tempel, K. Scheduled and unscheduled DNA synthesis in chick embryo liver following X-irradiation and treatment with DNA repair inhibitors in vivo. Int. J. Radiat. Biol., 56: 325-333, 1989.
36. Williams, G. M. Detection of chemical carcinogens by unscheduled DNA synthesis in rat liver primary cell cultures. Cancer Res., 37: 1845-1851, 1977.
37. McDonald, E. R., III, Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defect in p21WAF1/CIP1 -/-human cancer cells. Cancer Res., 56: 2250-2255, 1996.
38. Pietras, R. J., Arboleda, J., Reese, D., Wongvipat, N., Pegram, M., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10: 2435-2446, 1995.
39. Feinberg, A. P., and Vogelstein, B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132: 6-13, 1987.
40. Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15: 537-547, 1997.
41. Whitaker, S. J. DNA damage by drugs and radiation. Eur. J. Cancer. 28: 273-276, 1992.
42. Pirollo, K. F., Hoo, Z., Rait, A., Ho, C. W., and Chang, E. H. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem. Biophys. Res. Commun., 230: 196-201, 1997.
43. Akashi, M., Hachiya, M., Osawa, Y., Spirin, K., and Suzuki, G. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J. Biol. Chem., 270: 19181-19187, 1995.
44. Bacus, S. S., Yarden, Y., Oren, M., Chin, D. M., Lyass, L., Zelnick, C. R., Kazarov, A., Toyofuku, W., Gray-Bablin, J., Beerli, R. R., Hynes, N. E., Nikiforov, M., Haffner, R., Gudkov, A., and Keyomarsi, K. Neu differentiation factor (heregulin) activates a p53-dependent pathway in cancer cells. Oncogene, 12: 2535-2547, 1996.
45. Meek, D. W., Campbel, L. E. Jardine, L. J., Knippschild, U., McKendrick, L., and Milne, D. M. Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage. Biochem. Soc. Trans., 25: 416-419, 1997.
46. Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D. M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 90: 425-435, 1997.
47. Chen, I-T., Akamatsu, M., Smith, M. L., Lung, F-D., Duba, D., Roller, P. R., Fornace, A. J., Jr., and O'Connor, P. M. Characterization of p21CIP1/WAF1 peptide domains required for cyclin E/cdk2 and PCNA interaction. Oncogene, 12: 595-607, 1996.
48. Wu, G. S., and El-Deiry, S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin. Cancer Res., 2: 623-633, 1996.
49. Piette, J., Neel, H., and Marechal, V. Mdm2: keeping p53 under control. Oncogene, 15: 1001-1010, 1997.
50. Thut, C. J., Goodrich, J. A., and Tijan, R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev., 11: 1974-1986, 1997.
51. Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., Sliwkowski, M. X., and Slamon, D. J. Monoclonal antibody to HER-2 receptor modulates DNA repair and radiation sensitivity in human breast and ovarian cancer cells. Proc. Am. Assoc. Cancer Res., 37:4166, 1996.
52. Marte, B., Graus-Porta, D., Jeschke, M., Fabbro, D., Hynes, N., and Taverna, D. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene, 10: 167-175, 1995.
53. Sarup, J. C., Johnson, R. M., King, K. L., Fendly, B. M., Lipari, M. T., Napier, M. A., Ullrich, A., and Shepard, H. M. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul., 1: 72-82, 1991.
54. Graus-Porta, D., Beerli, R., and Hynes, N. Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol.. 15: 1182-1191, 1995.
55. Tsai, C-M., Levitzki, A., Wu, L-H., Chang, K-T., Cheng, C-C., Gazit, A., and Perng, R-P. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185neu expressing non-small cell lung carcinoma cells. Cancer Res., 56: 1068-1074, 1996.